Citadel Advisors LLC Takes Position in Rallybio Corporation $RLYB

Citadel Advisors LLC purchased a new stake in Rallybio Corporation (NASDAQ:RLYB) in the second quarter, HoldingsChannel reports. The firm purchased 72,200 shares of the company’s stock, valued at approximately $1,155,000.

Other institutional investors have also recently bought and sold shares of the company. XTX Topco Ltd lifted its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares in the last quarter. Susquehanna International Group LLP increased its stake in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the period. Geode Capital Management LLC increased its stake in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the period. BlackRock Inc. raised its position in shares of Rallybio by 73.5% during the second quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock worth $485,000 after acquiring an additional 12,846 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

Rallybio Stock Performance

Shares of RLYB stock opened at $16.75 on Friday. The firm’s 50 day moving average price is $16.44 and its two-hundred day moving average price is $13.45. Rallybio Corporation has a 52-week low of $3.67 and a 52-week high of $17.57. The stock has a market cap of $88.94 million, a PE ratio of -3.86 and a beta of -0.85.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, August 6th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.28) by $0.19. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on RLYB shares. Wall Street Zen upgraded Rallybio from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings raised Rallybio from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Rallybio currently has a consensus rating of “Hold”.

Rallybio Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.